

## Table of Contents

<b>1</b>	<b>Historical Review</b>	<b>1</b>
1.1	The Early Period (1898–1911)	1
1.2	Frustration and Successes (1912–1950)	2
1.3	The Period from 1950 to 1965	3
1.4	A First Human Tumorvirus?	5
1.5	The Difficult 1970s	6
1.6	The Re-Emergence of a Concept	7
	References	10
<b>2</b>	<b>The Quest for Causality</b>	<b>17</b>
2.1	Infectious Agents as Direct Carcinogens	20
2.2	Infectious Agents as Indirect Carcinogens	22
2.2.1	Induction of Chromosomal Aberrations	23
	References	25
<b>3</b>	<b>Tumors Linked to Infections: Some General Aspects</b>	<b>27</b>
3.1	Tumor Types Linked to Infections	27
3.2	Global Contributions of Infections to Human Cancers	28
3.3	Host Interactions with Potentially Carcinogenic Infections: The CIF Concept	30
3.3.1	The CIF-I Cascade	32
3.3.2	The CIF-II Cascade	34
3.3.3	The CIF-III Cascade	35
	References	38
<b>4</b>	<b>Herpesviruses and Oncogenesis</b>	<b>41</b>
	References	43
4.1	Alphaherpesvirinae	44
4.1.1	Herpes Simplex Viruses Types 1 and 2	44
4.1.2	Varicella-Zoster Virus	47
	References	47
4.2	Betaherpesvirinae	51
4.2.1	Human Cytomegalovirus	51

4.2.2	Human Herpesvirus Type 6	54
	References	60
4.3	Gammaherpesvirinae (Lymphocryptoviruses)	65
4.3.1	Epstein–Barr Virus	65
4.3.1.1	Characterization of the Virus, and its Biological Properties	66
4.3.1.2	EBV Gene Products in Latent Infection	67
4.3.1.3	Transforming Properties of EBV and Tumor Induction in Animals	72
4.3.1.4	Various Stages of Epstein–Barr Viral Latency	74
4.3.1.5	EBV in Infectious Mononucleosis	76
4.3.1.6	EBV in X-Chromosome-Linked Lymphoproliferative Disease	77
4.3.1.7	EBV in Immunoblastic Lymphoma	77
4.3.1.8	EBV in Burkitt’s Lymphoma	78
4.3.1.9	EBV in Nasopharyngeal Carcinoma	83
4.3.1.10	EBV in Hodgkin’s Disease	88
4.3.1.11	EBV in Gastric and Esophageal Carcinomas	92
4.3.1.12	EBV in NK/T-Cell Lymphomas	94
4.3.1.13	EBV and Other Human Cancers	95
	References	95
4.4	Rhadinoviruses	118
4.4.1	Human Herpesvirus Type 8 (HHV-8, Kaposi’s sarcoma-associated herpesvirus)	118
4.4.1.1	Historical Background	118
4.4.1.2	Epidemiology and Mode of Transmission	119
4.4.1.3	Pathogenesis: Other Diseases Associated with HHV-8 Infections	121
4.4.1.4	Viral Genes Expressed in Viral Latency	122
4.4.1.5	Cellular Genes Regulating Viral Latency	126
4.4.1.6	Interaction Between HIV and HHV-8	127
4.4.1.7	Viral Homologues to Host Cell Genes and Evasion from the Host’s Immune Mechanisms	128
4.4.1.8	HHV-8-Related Herpesviruses in Nonhuman Primates	131
4.4.2	Marek’s Disease of Chickens	132
	References	132
<b>5</b>	<b>Papillomavirus Infections: A Major Cause of Human Cancers</b>	<b>145</b>
5.1	Introduction	145
5.1.1	Structure of the Viral Particle, Transcriptional Regulation, and Taxonomy	146
5.1.2	Transmission and Natural History of Papillomavirus Infections	152
5.1.3	Functions of Viral Proteins	153
5.1.3.1	E6	153
5.1.3.2	E6*	157
5.1.3.3	E7	157
5.1.3.4	E5	162
5.1.3.5	E1	163
5.1.3.6	E2	164

5.1.3.7	E4	165
5.2	The Concept of Cellular Interfering Cascades: Immunological, Intracellular and Paracrine Host Factors Influencing Viral Oncogene Expression or Function	166
5.2.1	Immunological Control	167
5.2.2	CIF-I: Recognition System and its Disturbance	168
5.2.3	CIF-II: Intracellular Control of Viral Oncoprotein Functions	169
5.2.4	CIF-III: Paracrine Control	171
5.3	Cancers Linked to HPV Infections	174
5.3.1	Cancer of the Cervix	174
5.3.2	Penile Cancer	177
5.3.3	Vulvar Cancer	177
5.3.4	Vaginal Cancer	178
5.3.5	Perianal and Anal Cancer	178
5.3.6	Cancer of the Head and Neck	179
5.3.7	Other Cancers	181
5.3.7.1	Breast Cancer	181
5.3.7.2	Prostate Cancer	181
5.3.7.3	Lung Cancer	181
5.3.7.4	Colon and Rectum Cancers	182
5.3.7.5	Ovarian Cancer	182
5.3.7.6	Bladder Cancer	182
5.3.7.7	Nasal, Sinonasal and Conjunctival Cancers	183
5.3.7.8	Cancer of the Larynx	183
5.3.7.9	Cancer of the Esophagus	184
5.3.8	Cutaneous Papillomavirus Infections and Skin Cancer	185
5.4	The Role of Cofactors	188
5.4.1	Non-Infectious Cofactors	188
5.4.1.1	Smoking	188
5.4.1.2	Hormones and Hormonal Contraceptive Use	189
5.4.1.3	Parity	190
5.4.1.4	Nutrients	190
5.4.2	Infectious Cofactors	191
5.4.2.1	Herpes viruses	191
5.4.2.2	<i>Chlamydia trachomatis</i>	192
5.4.2.3	Human Immunodeficiency Virus	193
5.4.2.4	Other Infections	193
5.5	Preventive Vaccination	194
5.6	Therapeutic Vaccination	195
5.7	Therapy	197
	References	198
<b>6</b>	<b>Hepadnaviruses</b>	<b>244</b>
6.1	Hepatitis B	244
6.1.1	Historical Aspects	244

6.1.2	Epidemiology and Clinical Symptoms	245
6.1.3	Taxonomy and Viral Genome Structure	248
6.1.4	Viral Gene Products and Functions	250
6.1.4.1	Core Antigen	250
6.1.4.2	Polymerase	250
6.1.4.3	HB X Antigen	251
6.1.5	Pathogenesis and Immune Interactions	253
6.1.6	Role in Hepatocellular Carcinoma	254
6.1.6.1	HBx Transgenic Mice and HCCs	254
6.1.6.2	HBS Transgenic Mice and HCCs	255
6.1.7	Interaction of Hepatitis B Infection with Chemical Carcinogens (Aflatoxins and Alcohol)	257
6.1.7.1	Alcohol	257
6.1.7.2	Aflatoxin	257
6.1.8	Mechanism of HBV-Mediated Oncogenesis	258
6.1.9	Prevention and Control of HBV-Mediated Infections	259
6.1.9.1	Prevention	259
6.1.9.2	Therapy	260
	References	261
<b>7</b>	<b>Flaviviruses</b>	<b>274</b>
7.1	Hepatitis C Virus	274
7.1.1	History	274
7.1.2	Epidemiology	274
7.1.3	Viral Genome Structure, Transcription, Translation, Gene Functions, and Taxonomy	276
7.1.4	Infection, Transmission, and Viral DNA Persistence	277
7.1.5	Pathogenesis and Immune Interactions	278
7.1.5.1	Evasion of Host Defense Mechanisms	278
7.1.5.2	Host Immune Responses	280
7.1.6	Role in Hepatocellular Carcinoma	281
7.1.6.1	Experimental Evidence for a Role of HCV in Liver Cancer	281
7.1.7	Role in Lymphoproliferative Diseases	286
7.1.7.1	Mixed Cryoglobulinemia	286
7.1.7.2	Splenic Lymphoma with Villous Lymphocytes	286
7.1.7.3	Non-Hodgkin's Lymphoma	287
7.1.8	Prevention and Control	288
7.1.8.1	Vaccines	288
7.1.8.2	Therapy	288
	References	289
<b>8</b>	<b>Retrovirus Family</b>	<b>304</b>
8.1	Human T-Lymphotropic Retrovirus (HTLV-1)	306
8.1.1	Historical Background	306
8.1.2	Epidemiology and Transmission	306

8.1.3	Viral Gene Organization and Gene Products	307
8.1.3.1	The gag Protein	307
8.1.3.2	HTLV Protease	308
8.1.3.3	The Polymerase Protein	308
8.1.3.4	The env Protein	309
8.1.3.5	The Tax Protein	309
8.1.3.6	The Rex Protein	311
8.1.3.7	The p12(I) Protein	312
8.1.3.8	The p30(II) Protein	313
8.1.3.9	The p13(II) Protein	313
8.1.4	Diseases Caused by HTLV-1 Infection	314
8.1.5	Immune Response to HTLV-1 Infections	314
8.1.6	Animal Studies	316
8.1.7	Mechanism of Cell Transformation by HTLV-1	317
8.1.8	Prevention and Therapy	319
	References	319
8.2	Human T-Lymphotropic Retrovirus-2 (HTLV-2)	337
	References	339
8.3	Human Endogenous Retroviruses	341
8.3.1	The Discovery of HERVs	342
8.3.2	Genome Organization and Transcription	343
8.3.2.1	HERV-K	343
8.3.2.2	HERV-H	345
8.3.2.3	HERV-W	346
8.3.2.4	Other Endogenous Human Retrovirus Genomes	347
8.3.3	HERV Proteins and the Immune Response	347
8.3.4	HERV: The Role in Human Tumors and Autoimmune Diseases	348
8.3.5	The Trojan Exosome Hypothesis	351
	References	351
8.4	Gibbon Ape Leukemia Virus and Simian Sarcoma Virus	361
	References	364
<b>9</b>	<b>Other Virus Infections Possibly Involved in Human Cancers</b>	<b>366</b>
9.1	Polyomaviruses (JC, BK, and SV40)	366
9.1.1	BK Virus	368
9.1.1.1	Tumorigenicity of BK Virus in Experimental Animals	369
9.1.1.2	Immortalization of Human Cells by BK Virus, and BK Virus in Human Cancers	369
9.1.2	JC Virus	370
9.1.2.1	Tumorigenicity of JC Virus in Experimental Animals	370
9.1.2.2	Immortalization of Human Cells by JC Virus, and JC Virus in Human Cancers	371
9.1.3	SV40	373
9.1.3.1	Tumorigenicity of SV40 in Experimental Animals	373

9.1.3.2	Immortalization of Human Cells by SV40, and SV40 in Human Cancers	373
9.1.3.3	Does SV40 Represent a Human Carcinogen?	376
	References	377
<b>10</b>	<b>Helicobacter, Chronic Inflammation, and Cancer</b>	<b>386</b>
	<i>James G. Fox, Timothy C. Wang, and Julie Parsonnet</i>	
10.1	Discovery, Taxonomy, and Genomics	386
10.1.1	Discovery	386
10.1.1.1	Gastric Helicobacters	386
10.1.1.2	Enterohepatic Helicobacters	389
10.1.2	Taxonomy	390
10.1.2.1	Gastric Helicobacters	390
10.1.2.2	Enterohepatic Helicobacter spp.	391
10.1.3	Genomic Analysis	392
10.1.3.1	<i>H. pylori</i>	392
10.1.3.2	<i>H. hepaticus</i>	395
10.2	Life Cycle, Specificity, and Virulence Determinants in Cancer Development	396
10.2.1	Epidemiology of <i>H. pylori</i>	396
10.2.1.1	Transmission of <i>H. pylori</i>	398
10.2.1.2	Age of Acquisition	400
10.2.2	Bacterial Factors Responsible for Cell Specificity and Virulence	409
10.2.3	Host Factors Playing a Role in Gastric Diseases	412
10.2.4	Environmental Factors	413
10.2.4.1	Diet	414
10.2.4.2	Co-Infection	414
10.2.4.3	Bacterial Overgrowth	415
10.2.5	Natural History and Stages of Infection	416
10.2.6	Chronic Inflammation and Cancer	417
10.2.6.1	Reactive Oxygen/Nitrogen Species	418
10.2.6.2	Epithelial Cell Proliferation and Apoptosis	419
10.2.6.3	Role of Specific Cytokines	419
10.2.6.4	Link to T Cells and Macrophages	421
10.2.6.5	Bone Marrow Stem Cell Recruitment	422
10.3	Prevention of <i>H. pylori</i> -Induced Cancer	424
10.3.1	Interrupting Transmission in Children	424
10.3.2	Treatment Strategies of <i>H. pylori</i> in Populations at Risk	424
10.4	Animal Models	426
10.4.1	Animal Models for Helicobacter-Induced Gastric Cancer	426
10.4.1.1	Gerbil	426
10.4.1.2	Mouse	428
10.4.1.3	Ferret	430
10.4.2	Animal Models of MALT Lymphoma	432
10.4.2.1	<i>H. felis</i> -Induced MALT Lymphoma	432

10.4.3	Animal Models for Enterohepatic <i>Helicobacter</i> -Induced Cancer	433
10.4.3.1	<i>Helicobacter hepaticus</i> -Induced Liver Cancer	433
10.4.3.2	<i>Helicobacter bilis</i> -Associated Hepatitis	435
10.4.3.3	<i>Helicobacter hepaticus</i> and Lower Bowel Cancer	435
10.5	Virulence Determinants of Enterohepatic <i>Helicobacter</i> spp.	437
10.5.1	<i>H. hepaticus</i> is a Tumor Promoter in the Liver	437
10.5.2	<i>H. hepaticus</i> Increases ROS and Intestinal Tumors	438
10.5.3	<i>H. hepaticus</i> Pathogenicity Island	438
10.5.4	Cytotoxic Distending Toxin (CDT)	439
10.6	Enterohepatic <i>Helicobacter</i> spp.: Are they Co-Carcinogens?	440
	References	442
<b>11</b>	<b>Parasites and Human Cancers</b>	<b>468</b>
11.1	Schistosoma Infections	468
11.1.1	Epidemiology	470
11.1.2	Experimental Studies in Animals	471
11.1.3	Schistosoma Eggs and Cancer	472
11.1.4	Interactions of Schistosoma with Other Infections, and Chemical Factors	473
11.1.5	Mechanism of Schistosoma-Induced Cancers	474
11.1.6	Control and Therapy	474
	References	474
11.2	Infection with Liver Flukes ( <i>Opisthorchis viverrini</i> , <i>O. felineus</i> , <i>Clonorchis sinensis</i> )	477
11.2.1	Epidemiology	478
11.2.2	Immune Response	480
11.2.3	Role of Liver Flukes in Human Cancer, and Studies in Animals	480
11.2.4	Mechanism of Carcinogenicity	481
11.2.5	Control and Therapy	481
	References	482
<b>12</b>	<b>Cancers with a Possible Infectious Etiology</b>	<b>485</b>
12.1	Leukemias and Lymphomas	485
12.1.1	Epidemiological Data	486
12.1.2	The Target Cell Conditioning Model	492
	References	495
12.2	Human Breast Cancer	500
12.3	Other Human Cancers Possibly Linked to Infectious Events	502
	References	503